Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for Sleep Disturbance in Atopic Dermatitis
NCT06390722Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: Percentage of participants achieving an improvement (reduction) in Worst Pruritus Numeric Rating Scale ≥ 4 from Baseline at 2 weeks. Planned start May 2024; status: withdrawn.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06390722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390722.